Artara Therapeutics Inc (TARA)

$6.50 -0.21 (-3.13%)
Market Cap 346.44M
Revenue (ttm) 0.00
Net Income (ttm) -44.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 708,000
Avg Vol 1,065,240
Day's Range N/A - N/A
Shares Out 51.63M
Stochastic %K 35%
Beta 1.38
Analysts Strong Sell
Price Target $25.50

Company Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving pare...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 844 0337
Address:
345 Park Avenue South, 3rd Floor, New York, United States
Eagley3k
Eagley3k Feb. 4 at 11:19 PM
$TARA i personally dont have a say about the upside move but here is what Cown thinks - upside move : 80% - 100% - downside risk : 20% - 30%
0 · Reply
Eagley3k
Eagley3k Feb. 3 at 9:21 PM
$TARA hope you're happy
0 · Reply
RandomInvestor777
RandomInvestor777 Feb. 3 at 6:43 PM
$TARA how important is the catalyst on feb? could it support a 2x to 15-20?
0 · Reply
SushiYoshi
SushiYoshi Jan. 30 at 6:37 PM
$TARA $IREN $NBIS i love my data center more than everything, but Tara is such a broken stock, no rule , red market, always green 😂
1 · Reply
lovestockstwits
lovestockstwits Jan. 28 at 3:07 PM
$TARA never seen this one red ..always green
0 · Reply
hbkstockislife
hbkstockislife Jan. 27 at 11:35 PM
$TARA everyday up literally everyday
1 · Reply
RakeTheProfit
RakeTheProfit Jan. 27 at 9:11 PM
$TARA how this one is still under the radar on Stocktwits is beyond me! 🔥
0 · Reply
Drugtrade
Drugtrade Jan. 27 at 7:20 PM
$TARA upcoming: Q1 2026: Interim results from ADVANCED-2.. 1H 2026: Regulatory update on the path to registration for TARA-002.. Total Cash: ~$132.67 m
1 · Reply
SushiYoshi
SushiYoshi Jan. 26 at 8:08 PM
$TARA Aged like a fine wine
0 · Reply
Bigeyes2
Bigeyes2 Jan. 25 at 8:28 PM
$TARA cup and handle & gap to fill
0 · Reply
Latest News on TARA
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 4:05 PM EST - 3 days ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

Jan 22, 2026, 8:00 AM EST - 14 days ago

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 12:25 AM EST - 22 days ago

Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Jan 12, 2026, 7:00 AM EST - 24 days ago

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:00 AM EST - 4 weeks ago

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Jan 5, 2026, 8:00 AM EST - 4 weeks ago

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Announces Closing of $75 Million Public Offering

Dec 8, 2025, 4:05 PM EST - 2 months ago

Protara Announces Closing of $75 Million Public Offering

Protara Announces Pricing of $75 Million Public Offering

Dec 4, 2025, 10:03 PM EST - 2 months ago

Protara Announces Pricing of $75 Million Public Offering

Protara Announces Proposed Public Offering

Dec 4, 2025, 4:15 PM EST - 2 months ago

Protara Announces Proposed Public Offering

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Dec 4, 2025, 7:30 AM EST - 2 months ago

Protara Therapeutics: End Of 2025 Proving Eventful Indeed

Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript

Dec 3, 2025, 3:43 PM EST - 2 months ago

Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients Transcript

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Dec 3, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Dec 1, 2025, 4:15 PM EST - 2 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025

Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Nov 19, 2025, 2:53 PM EST - 2 months ago

Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Nov 19, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Nov 18, 2025, 4:30 PM EST - 2 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Nov 17, 2025, 8:00 AM EST - 2 months ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 3 months ago

Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Nov 4, 2025, 4:05 PM EST - 3 months ago

Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace

Protara Therapeutics to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 5 months ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 8:00 AM EDT - 6 months ago

Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics Announces Addition to the Russell 3000® Index

Jun 30, 2025, 8:00 AM EDT - 7 months ago

Protara Therapeutics Announces Addition to the Russell 3000® Index

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

Jun 2, 2025, 4:04 PM EDT - 8 months ago

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 9 months ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Apr 26, 2025, 10:00 AM EDT - 10 months ago

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Apr 15, 2025, 4:13 PM EDT - 10 months ago

Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Apr 10, 2025, 4:05 PM EDT - 10 months ago

Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Mar 28, 2025, 5:10 PM EDT - 11 months ago

Protara Therapeutics: Speculative Buy On Promising TARA-002 Trial Results

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Mar 19, 2025, 8:00 AM EDT - 11 months ago

Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Mar 5, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Jan 13, 2025, 8:00 AM EST - 1 year ago

Protara Highlights Recent Updates and Anticipated 2025 Milestones

Protara Therapeutics: Rising From The Ashes

Dec 14, 2024, 8:30 AM EST - 1 year ago

Protara Therapeutics: Rising From The Ashes

Protara Announces Closing of $100 Million Public Offering

Dec 11, 2024, 4:05 PM EST - 1 year ago

Protara Announces Closing of $100 Million Public Offering

Protara Therapeutics: Carving New Roads In Bladder Cancer

Dec 10, 2024, 5:00 PM EST - 1 year ago

Protara Therapeutics: Carving New Roads In Bladder Cancer

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Dec 10, 2024, 3:55 PM EST - 1 year ago

Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst

Protara Announces Pricing of $100 Million Public Offering

Dec 9, 2024, 11:35 PM EST - 1 year ago

Protara Announces Pricing of $100 Million Public Offering

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Dec 5, 2024, 10:50 AM EST - 1 year ago

Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday?

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Nov 15, 2024, 5:52 PM EST - 1 year ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Nov 6, 2024, 8:00 AM EST - 1 year ago

Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Sep 9, 2024, 8:05 AM EDT - 1 year ago

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 24, 2024, 5:06 PM EDT - 1 year ago

Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Apr 5, 2024, 8:04 AM EDT - 1 year ago

Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Apr 5, 2024, 8:02 AM EDT - 1 year ago

Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition

Eagley3k
Eagley3k Feb. 4 at 11:19 PM
$TARA i personally dont have a say about the upside move but here is what Cown thinks - upside move : 80% - 100% - downside risk : 20% - 30%
0 · Reply
Eagley3k
Eagley3k Feb. 3 at 9:21 PM
$TARA hope you're happy
0 · Reply
RandomInvestor777
RandomInvestor777 Feb. 3 at 6:43 PM
$TARA how important is the catalyst on feb? could it support a 2x to 15-20?
0 · Reply
SushiYoshi
SushiYoshi Jan. 30 at 6:37 PM
$TARA $IREN $NBIS i love my data center more than everything, but Tara is such a broken stock, no rule , red market, always green 😂
1 · Reply
lovestockstwits
lovestockstwits Jan. 28 at 3:07 PM
$TARA never seen this one red ..always green
0 · Reply
hbkstockislife
hbkstockislife Jan. 27 at 11:35 PM
$TARA everyday up literally everyday
1 · Reply
RakeTheProfit
RakeTheProfit Jan. 27 at 9:11 PM
$TARA how this one is still under the radar on Stocktwits is beyond me! 🔥
0 · Reply
Drugtrade
Drugtrade Jan. 27 at 7:20 PM
$TARA upcoming: Q1 2026: Interim results from ADVANCED-2.. 1H 2026: Regulatory update on the path to registration for TARA-002.. Total Cash: ~$132.67 m
1 · Reply
SushiYoshi
SushiYoshi Jan. 26 at 8:08 PM
$TARA Aged like a fine wine
0 · Reply
Bigeyes2
Bigeyes2 Jan. 25 at 8:28 PM
$TARA cup and handle & gap to fill
0 · Reply
Eagley3k
Eagley3k Jan. 25 at 1:11 PM
$PVLA $TARA is there a chance if the government shuts down, data could be delayed?? Appreciate well informed investors' opinion
1 · Reply
SuperGreenToday
SuperGreenToday Jan. 24 at 4:27 PM
$TARA Share Price: $6.20 Contract Selected: Aug 21, 2026 $5 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.18 – $2.66 Potential Upside: 61% ROI Time to Expiration: 208 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Rolo2024
Rolo2024 Jan. 22 at 3:22 PM
$TARA Presentations take place in San Francisco February 26 & 28!!! Mark your calendars this could be the catalyst!
1 · Reply
Longbuy1
Longbuy1 Jan. 22 at 2:50 PM
$TARA In 20k shares.
0 · Reply
DARKP00L
DARKP00L Jan. 22 at 1:15 PM
$TARA 08:04 on Jan. 22 2026 Protara Therapeutics To Feature Interim Data From Cohort Of BCG-Unresponsive NMIBC Patients In Ongoing Phase 2 ADVANCED-2 Trial Of TARA-002 At Upcoming ASCO GU #tradeideas
1 · Reply
GreedyD
GreedyD Jan. 21 at 3:41 PM
$TARA another 20% winner with this. Re-entry at $5.50 🤞🏻
1 · Reply
SushiYoshi
SushiYoshi Jan. 21 at 12:29 AM
$TARA It's doing the november move again, market is red....Tara is green I love that Tara !!
0 · Reply
topstockalerts
topstockalerts Jan. 20 at 7:42 PM
$TARA Looks primed for another leg higher. Buyers are still pressing. This trend may not be done yet.
0 · Reply
SunriseMorning
SunriseMorning Jan. 20 at 6:29 PM
$TARA dang up and up
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 20 at 5:56 PM
$TARA Current Stock Price: $5.44 Contracts to trade: $5 TARA Feb 20 2026 Call Entry: $0.60 Exit: $1.00 ROI: 67% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
lovestockstwits
lovestockstwits Jan. 16 at 10:31 PM
$TARA IBRX is way ahead and will file for NDA soon
3 · Reply
Rolo2024
Rolo2024 Jan. 16 at 7:01 PM
$TARA Theres enough cash on hand for 3 years and revenues potentially will not start until 4 years. Let's trust our data that we will receive breakout news in 1-2 years that will propel this stock into double digits $10-$12 by end of the year. Sporting around a $3 average so this will be better that putting into a dividend stock for now.
0 · Reply